NeuroNOS

A Biotech company solely focused on brain disorders, pioneering a unique platform to develop a new class of therapies for Autism, Alzheimer's, and Glioblastoma.

[NeuroNOS @Neuro_NOS]

Proud to share: the FDA has granted Orphan Drug Designation to BA-101 for Glioblastoma (GBM) — the most common malignant brain cancer in adults.
This is our 2nd ODD in 2025, advancing our mission to deliver targeted nitric-oxide–modulating therapies.
https://t.co/2O6waGw3mA

[PRISM MarketView @PrismMarketView]

(Nasdaq: $XAIR)
@Neuro_NOS , a Beyond Air subsidiary, has been granted FDA Orphan Drug Designation for BA-101 in glioblastoma, one of the deadliest brain cancers. With few advances in treatment in decades, BA-101’s nitric oxide modulation approach could represent a breakthrough for patients.

https://t.co/X2vXiQk6Hf

[NeuroNOS @Neuro_NOS]

Glioblastoma (GBM) is the most aggressive brain cancer, with survival often measured in months despite current treatments.
At NeuroNOS, we’re developing a novel nNOS inhibitor to rebalance nitric oxide signaling that fuels tumor growth.
#NeuroNOS #Glioblastoma #braincancercure

[NeuroNOS @Neuro_NOS]

In a landmark Redox Biology review, our CSO Prof. @haitham_amal (@NeuroNOS) with Tripathi & Kartawy highlighted how NO dysregulation drives brain disorders.
We’re building on these insights with a selective nNOS inhibitor for ASD. @Elsevier
#NeuroNOS #AutismResearch #NitricOxide

[NeuroNOS @Neuro_NOS]

We’re proud our CSO, Prof. @haitham_amal, will speak at #Synchrony2025 on Aug 22! His nitric oxide work shapes our mission at @Neuro_NOS.
Thanks to the BRAIN foundation, @BostonChildrens, @HebrewU, and the Rosamund Stone Zander Center for advancing this dialogue
#AutismResearch

[NeuroNOS @Neuro_NOS]

#ThrowbackThursday: Prof. @haitham_amal’s lab (our CSO) found disrupted autophagy proteins in two ASD models, driven by NO imbalance. Blocking nNOS restored normal function—reinforcing NeuroNOS’s approach to rebalance NO & tackle core ASD biology. #AutismResearch #NeuroNOS

[NeuroNOS @Neuro_NOS]

Nitric oxide (NO) is vital in balance, too much from nNOS fuels nitrosative stress, disrupting synapses. Research by our CSO, Prof. @haitham_amal, links this to ASD. At NeuroNOS, we’re developing a selective nNOS inhibitor to restore brain balance.
#ASD #BrainHealth #NitricOxide

[NeuroNOS @Neuro_NOS]

#ThrowbackThursday: A 2022 Free Radical Biology & Medicine paper by @haitham_amal revealed how nitric oxide disrupts NMDA receptor signaling in ASD models.

At NeuroNOS, we’re targeting that biology with our selective nNOS inhibitor.

#ASD #NitricOxide #TBT @ElsevierConnect

[NeuroNOS @Neuro_NOS]

Lifetime autism care may exceed $4M per person (Zhao et al., 2024). Most treatments manage symptoms, few target root biology.

At NeuroNOS, we’re developing a first-in-class drug to rebalance NO signaling in ASD.

#NeuroNOS #Autism #ASD #NitricOxide #HealthEconomics

[NeuroNOS @Neuro_NOS]

📽️Sneak peak: We spoke with three world-class scientists, joined by our two extraordinary Nobel Laureates who serve on our Scientific Advisory Board (SAB), as well as our CSO, to discuss our novel small-molecule nitric oxide inhibition platform for autism.
#NobelPrize #Autism

[NeuroNOS @Neuro_NOS]

Proud to share that our CSO, Prof. @haitham_amal Amal, joins the #Synchrony2025 Roundtable on neuroenergetics in autism.

Excess NO → oxidative stress → mitochondrial strain. Our nNOS-targeted small molecule aims to restore balance. #NO #Autism

https://t.co/HTQBOnZhFq

[NeuroNOS @Neuro_NOS]

🔙 #ThrowbackThursday: 2023 Adv Sci paper “The NO answer for ASD” showed that nitric‑oxide modulation can reverse autism‑like behavior 👉 https://t.co/pwbpG1LkcN

@NeuroNOS is turning that insight into a first‑in‑human nNOS small‑molecule trial in 2026.
#NO #Autism #ASD

[NeuroNOS @Neuro_NOS]

We're honored to be highlighted by @brainfdn for our work on nitric oxide modulation in #autism.
Proud to share the science — and the stage — at #Synchrony2025.
https://t.co/FzeAZEc5BN
#NeuroNOS #NitricOxide #TranslationalResearch #ASD #CNS #DrugDevelopment

[NeuroNOS @Neuro_NOS]

🎧 Prof. @haitham_amal, CSO @NeuroNOS, explains how NO dysregulation drives Phelan‑McDermid Syndrome (PMS) & how our FDA‑orphan small molecule advances to first‑in‑human trials in 2026. Watch ▶️ https://t.co/9JT8589bzl
#PMSF #CureSHANK #RareDisease #Autism #DrugDiscovery

[NeuroNOS @Neuro_NOS]

@Neuro_NOS is excited to share the BIG news from the #FDA! The #FDA granted us an Orphan Drug Designation for #PhelanMcDermidSyndrome, a Neurodevelopmental Disorder Linked to #Autism #OrphanDrug #NitricOxide #PMS #RareDisease
https://t.co/uVzF31IKBH